Biotech Focus: Tracking the Oncology Pipeline

Published: Wednesday, Feb 13, 2013

2012 ASH Annual Meeting

ASH Several investigational treatments were highlighted at the 2012 American Society of Hematology Annual Meeting, which took place from December 8-11 in Atlanta, Georgia. View our complete coverage of the meeting.
  • Ibrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase, demonstrated dramatic activity in patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).

    In a 116-patient phase Ib/II study of patients with relapsed/refractory (RR) or treatment-naïve (aged ≥65 years) CLL or SLL, ibrutinib monotherapy was associated with estimated progression-free survival rates of 96% and 76% in the treatment-naïve and RR groups, respectively. The maximum follow-up was 26 months.

    In a second study, researchers sought to accelerate response to ibrutinib by pairing the drug with rituximab in 40 patients with CLL/SLL (median age, 65 years) considered high risk. In all, 38 of 40 patients continued on therapy without disease progression. The overall response rate (ORR) was 83%.

    A third trial demonstrated that singleagent ibrutinib had an “unprecedented” ORR of 66.1% in 109 evaluable patients with relapsed or refractory MCL (median age, 68 years). The ongoing phase II study included both bortezomib-naïve and bortezomib-exposed patients.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication